Horizon Discovery Collaborate with Top Ten Pharma Company
News Oct 15, 2014
Horizon Discovery Group plc, has announced that its Horizon CombinatoRx division has been contracted by a top ten pharma company to profile a lead oncology asset. Under the terms of the agreement, Horizon CombinatoRx will be paid approximately USD $450,000 (GBP £276,000) for work to be completed within a six month period.
Horizon will provide services to support proof-of-concept, monotherapy screening, and combination screening for the lead asset. Horizon CombinatoRx provides its partners access to the unique cHTS platform and Chalice™ analytics software, which enable the screening and analysis of thousands of complementary drug combinations. Combined with Horizon’s GENESIS™ (rAAV, CRISPR and ZFN) gene editing platform and X-MAN™ isogenic cell line technology, Horizon CombinatoRx offers services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.
Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “We are delighted that Horizon CombinatoRx continues to gain traction in the market, following the acquisition earlier this year. This latest contract with a top ten pharma in the oncology space continues to demonstrate the potential of this business and the value Horizon CombinatoRx can offer to support key drug discovery and development programs in cancer.”
Horizon Discovery completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc. in June 2014.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE